Teva Pharmaceutical Industries Ltd. TEVA announces the launch of the
generic equivalent to Zemplar® (paricalcitol) tablets in the United States as
of September 30, 2013. Teva was first to file, making the product eligible for
180 days of marketing exclusivity.
Zemplar® (paricalcitol) Capsules are an active form of vitamin D used to
prevent and treat secondary hyperparathyroidism (increased parathyroid hormone
levels) in patients with Stage 3 or Stage 4 chronic kidney disease and in
Stage 5 patients on dialysis. It is an active form of vitamin D. Marketed by
AbbVie Inc., Zemplar® had annual sales of approximately $115 million in the
United States, according to IMS data as of June 30, 2013.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in